Skip to main content
. 2014 Dec 18;10(11):2053–2074. doi: 10.4161/15548627.2014.973737

Figure 5.

Figure 5.

Effects of cysteamine and EGCG on BECN1 and SQSTM1 protein levels in ex vivo cultured primary human nasal epithelial cells belonging to the enrolled F508del-CFTR homozygous CF patients. (A and B) Effects of ex vivo treatment on BECN1 and SQSTM1 protein levels in nasal epithelial cells. (A) Mean values of BECN1 and SQSTM1 of patients No. 5, 6 and 10 of Table 1. The values are expressed as percentage of non-CF healthy control (considered as 100% of value). Mean values of 3 independent experiments for each sample; °°P < 0.01 compared to untreated, ##P < 0.01 compared to non-CF healthy control (ANOVA). (B and C) Representative blot of BECN1 and SQSTM1 protein levels in nasal epithelial cells from (B) one out of 5 non-CF control and one patient (No. 10 of Table 1) out of 3 patients analyzed and (C) patient No. 10 cultured ex vivo, as indicated. Top, western blot analysis of insoluble and soluble protein fractions and immunoblot with anti-BECN1 (Abcam) and anti-SQSTM1 (Sigma Aldrich). ACTB was used as negative marker of the insoluble protein fraction and as loading control of the experiment. Bottom, densitometric measurement of BECN1 in the soluble fraction and SQSTM1 level in the insoluble protein fraction expressed as percentage of non-CF healthy control. Mean ± SD of triplicates of independent experiments; °°P < 0.01 compared to untreated, ##P < 0.01 compared to non-CF healthy control (ANOVA).